The $100 million Israel Biotech Fund (IBF), founded to invest in Israeli bio-techs, has made its first investment in cancer treatment developer Vidac.  Vida’s VDA-1102 is the first ointment that selectively targets malignant skin cancer cells with minimal effects on surrounding healthy skin.

http://www.globes.co.il/en/article-israel-biotech-fund-raises-100m-1001136253